Mats Jerkeman
131 – 140 of 176
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time
2011) Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem In Biology of Blood and Marrow Transplantation 17(2). p.196-196(
- Contribution to journal › Published meeting abstract
-
Mark
Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy
(
- Contribution to journal › Article
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
-
Mark
Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group.
(
- Contribution to journal › Article
- 2010
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(
- Contribution to journal › Article
-
Mark
Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
(
- Contribution to journal › Article
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
(
- Contribution to journal › Article
-
Mark
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
SOX11 expression correlates to promoter methylatuion and regulates tumor growth in hematopoietic malignancies
(
- Contribution to journal › Article